NO20003930L - Sammensetninger som inneholder organiske forbindelser - Google Patents

Sammensetninger som inneholder organiske forbindelser

Info

Publication number
NO20003930L
NO20003930L NO20003930A NO20003930A NO20003930L NO 20003930 L NO20003930 L NO 20003930L NO 20003930 A NO20003930 A NO 20003930A NO 20003930 A NO20003930 A NO 20003930A NO 20003930 L NO20003930 L NO 20003930L
Authority
NO
Norway
Prior art keywords
organic compounds
compositions containing
containing organic
compositions
compounds
Prior art date
Application number
NO20003930A
Other languages
English (en)
Other versions
NO20003930D0 (no
NO329376B1 (no
Inventor
Peter Van Hoogevest
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26313062&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20003930(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9802451.6A external-priority patent/GB9802451D0/en
Priority claimed from GBGB9813646.8A external-priority patent/GB9813646D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of NO20003930D0 publication Critical patent/NO20003930D0/no
Publication of NO20003930L publication Critical patent/NO20003930L/no
Publication of NO329376B1 publication Critical patent/NO329376B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
NO20003930A 1998-02-05 2000-08-03 Farmasoytiske formuleringer som inneholder organiske forbindelser, og anvendelse derav NO329376B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9802451.6A GB9802451D0 (en) 1998-02-05 1998-02-05 Organic compounds
GBGB9813646.8A GB9813646D0 (en) 1998-06-24 1998-06-24 Organic compounds
PCT/EP1999/000702 WO1999039694A2 (en) 1998-02-05 1999-02-03 Compositions containing organic compounds

Publications (3)

Publication Number Publication Date
NO20003930D0 NO20003930D0 (no) 2000-08-03
NO20003930L true NO20003930L (no) 2000-10-04
NO329376B1 NO329376B1 (no) 2010-10-04

Family

ID=26313062

Family Applications (2)

Application Number Title Priority Date Filing Date
NO20003930A NO329376B1 (no) 1998-02-05 2000-08-03 Farmasoytiske formuleringer som inneholder organiske forbindelser, og anvendelse derav
NO20100302A NO20100302L (no) 1998-02-05 2010-03-04 Sammensetninger som inneholder organiske forbindelser

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO20100302A NO20100302L (no) 1998-02-05 2010-03-04 Sammensetninger som inneholder organiske forbindelser

Country Status (36)

Country Link
US (5) US20030203876A1 (no)
EP (1) EP1052974B1 (no)
JP (2) JP4644364B2 (no)
KR (3) KR20060002022A (no)
CN (2) CN100396276C (no)
AR (1) AR017979A1 (no)
AT (1) ATE431733T1 (no)
AU (1) AU753519B2 (no)
BE (1) BE1012140A3 (no)
BR (1) BR9907647B1 (no)
CA (1) CA2320182C (no)
CL (1) CL2003002786A1 (no)
CO (1) CO4920246A1 (no)
CY (1) CY1109311T1 (no)
CZ (1) CZ303168B6 (no)
DE (1) DE69940904D1 (no)
DK (1) DK1052974T3 (no)
ES (1) ES2324378T3 (no)
FR (1) FR2774909B1 (no)
HU (1) HUP0101564A3 (no)
ID (1) ID26549A (no)
IL (2) IL137550A0 (no)
IT (1) IT1313549B1 (no)
MX (1) MXPA00007681A (no)
MY (1) MY125921A (no)
NO (2) NO329376B1 (no)
NZ (1) NZ506389A (no)
PE (1) PE20000272A1 (no)
PL (1) PL201329B1 (no)
PT (1) PT1052974E (no)
RU (1) RU2214246C2 (no)
SI (1) SI1052974T1 (no)
SK (2) SK287487B6 (no)
TR (1) TR200002299T2 (no)
TW (1) TW457095B (no)
WO (1) WO1999039694A2 (no)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6537579B1 (en) * 1993-02-22 2003-03-25 American Bioscience, Inc. Compositions and methods for administration of pharmacologically active compounds
EP1440973A3 (de) 1995-11-17 2004-10-20 Gesellschaft für biotechnologische Forschung mbH (GBF) Epothilonderivate, Herstellung und Mittel
ES2312695T3 (es) 1996-11-18 2009-03-01 Gesellschaft Fur Biotechnologische Forschung Mbh (Gbf) Epotilones e y f.
JP4579351B2 (ja) 1996-12-03 2010-11-10 スローン−ケッタリング インスティトュート フォア キャンサー リサーチ エポチロンの合成とその中間体及びその類似物並びにその使用
US6204388B1 (en) 1996-12-03 2001-03-20 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US6605599B1 (en) 1997-07-08 2003-08-12 Bristol-Myers Squibb Company Epothilone derivatives
US6365749B1 (en) 1997-12-04 2002-04-02 Bristol-Myers Squibb Company Process for the preparation of ring-opened epothilone intermediates which are useful for the preparation of epothilone analogs
GB9802451D0 (en) * 1998-02-05 1998-04-01 Ciba Geigy Ag Organic compounds
FR2775187B1 (fr) * 1998-02-25 2003-02-21 Novartis Ag Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo
US6498257B1 (en) 1998-04-21 2002-12-24 Bristol-Myers Squibb Company 2,3-olefinic epothilone derivatives
US6380395B1 (en) 1998-04-21 2002-04-30 Bristol-Myers Squibb Company 12, 13-cyclopropane epothilone derivatives
US6410301B1 (en) 1998-11-20 2002-06-25 Kosan Biosciences, Inc. Myxococcus host cells for the production of epothilones
US6303342B1 (en) 1998-11-20 2001-10-16 Kason Biosciences, Inc. Recombinant methods and materials for producing epothilones C and D
US6518421B1 (en) 2000-03-20 2003-02-11 Bristol-Myers Squibb Company Process for the preparation of epothilone analogs
US6593115B2 (en) 2000-03-24 2003-07-15 Bristol-Myers Squibb Co. Preparation of epothilone intermediates
US6589968B2 (en) 2001-02-13 2003-07-08 Kosan Biosciences, Inc. Epothilone compounds and methods for making and using the same
US8618085B2 (en) 2000-04-28 2013-12-31 Koasn Biosciences Incorporated Therapeutic formulations of desoxyepothilones
UA75365C2 (en) 2000-08-16 2006-04-17 Bristol Myers Squibb Co Epothilone analog polymorph modifications, a method for obtaining thereof (variants), a pharmaceutical composition based thereon
SK8552003A3 (en) 2001-01-25 2004-06-08 Bristol Myers Squibb Co Parenteral formulation containing epothilone analogs
IL156578A0 (en) * 2001-01-25 2004-01-04 Bristol Myers Squibb Co A method for formulating an epothilone analog for pharmaceutical use and pharmaceutical preparations including an epothilone analog
WO2002058699A1 (en) 2001-01-25 2002-08-01 Bristol-Myers Squibb Company Pharmaceutical forms of epothilones for oral administration
KR100851719B1 (ko) 2001-01-25 2008-08-11 브리스톨-마이어스스퀴브컴파니 암 치료용 에포틸론 유사체의 투여 방법
US6893859B2 (en) 2001-02-13 2005-05-17 Kosan Biosciences, Inc. Epothilone derivatives and methods for making and using the same
JP2004522771A (ja) 2001-02-20 2004-07-29 ブリストル−マイヤーズ　スクイブ　カンパニー 治療抵抗性腫瘍の処置用エポチロン誘導体
RU2003128311A (ru) 2001-02-20 2005-03-10 Бристол-Маерс Сквибб Компани (Us) Способ лечения резистентных опухолей с применением аналогов эпотилона
HU230273B1 (hu) 2001-03-14 2015-11-30 Bristol-Myers Squibb Company Egy epotilon analóg és kemoterápiás szerek kombinációja proliferatív betegségek kezelésére
PT1372650E (pt) * 2001-03-19 2009-02-25 Novartis Ag Associações compreendendo um agente antidiarreico e uma epotilona ou um derivado de epotilona
JP2004532888A (ja) 2001-06-01 2004-10-28 ブリストル−マイヤーズ　スクイブ　カンパニー エポチロン誘導体
TWI315982B (en) * 2001-07-19 2009-10-21 Novartis Ag Combinations comprising epothilones and pharmaceutical uses thereof
AU2008203233B2 (en) * 2001-07-19 2010-04-29 Novartis Ag Combinations comprising epothilones and pharmaceutical uses thereof
BR0306861A (pt) 2002-01-14 2004-11-03 Novartis Ag Combinações que compreendem epotilonas e antimetabólitos
AU2003218107A1 (en) 2002-03-12 2003-09-29 Bristol-Myers Squibb Company C12-cyano epothilone derivatives
TW200403994A (en) 2002-04-04 2004-03-16 Bristol Myers Squibb Co Oral administration of EPOTHILONES
TW200400191A (en) 2002-05-15 2004-01-01 Bristol Myers Squibb Co Pharmaceutical compositions and methods of using C-21 modified epothilone derivatives
DE60333754D1 (de) * 2002-06-10 2010-09-23 Novartis Ag Epothilone enthaltende kombinationen und deren pharmazeutische verwendungen
US7008936B2 (en) 2002-06-14 2006-03-07 Bristol-Myers Squibb Company Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases
PT1506203E (pt) 2002-08-23 2007-04-30 Sloan Kettering Inst Cancer Síntese de epotilonas, seus intermediários, seus análogos e suas utilizações
US7649006B2 (en) 2002-08-23 2010-01-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
TWI291464B (en) 2002-09-23 2007-12-21 Bristol Myers Squibb Co Methods for the preparation, isolation and purification of epothilone B, and X-ray crystal structures of epothilone B
US7091193B2 (en) 2002-10-09 2006-08-15 Kosan Biosciences Incorporated Therapeutic formulations
SI1553938T1 (sl) * 2002-10-15 2007-06-30 Univ Louisiana State Uporaba epotilonskih derivatov za zdravljenje hiperparatiroidizma
DE60330703D1 (de) 2002-11-07 2010-02-04 Kosan Biosciences Inc Trans-9,10-dehydroepothilon c und d, analoga davon und verfahren zu deren herstellung
WO2005034964A1 (en) * 2003-10-09 2005-04-21 Kosan Biosciences, Inc. Therapeutic formulations
AU2004280252A1 (en) * 2003-10-09 2005-04-21 Kosan Biosciences, Inc. Therapeutic formulations
US20050171167A1 (en) * 2003-11-04 2005-08-04 Haby Thomas A. Process and formulation containing epothilones and analogs thereof
JPWO2005073223A1 (ja) * 2004-01-29 2007-09-13 エーザイ・アール・アンド・ディー・マネジメント株式会社 マクロライド系化合物の安定化方法
US20060121511A1 (en) 2004-11-30 2006-06-08 Hyerim Lee Biomarkers and methods for determining sensitivity to microtubule-stabilizing agents
EP1674098A1 (en) * 2004-12-23 2006-06-28 Schering Aktiengesellschaft Stable and tolerable parental formulations of highly reactive organic drug substances with low or no solubility in water
CN100409846C (zh) * 2005-11-22 2008-08-13 菏泽睿鹰制药集团有限公司 一种埃坡霉素b脂质体制剂及应用
AR062375A1 (es) 2006-08-16 2008-11-05 Novartis Ag Cristal de epotilona b y composiciones farmaceuticas
EP2210584A1 (en) 2009-01-27 2010-07-28 Bayer Schering Pharma Aktiengesellschaft Stable polymeric composition comprising an epothilone and an amphiphilic block copolymer
CN101642453B (zh) * 2009-09-15 2011-03-16 湖南迪诺制药有限公司 一种含有埃坡霉素b的药物制剂
GB201505347D0 (en) * 2015-03-27 2015-05-13 Salupont Consulting Ltd Sterilisation of s-nitrosothiols
AU2018341136A1 (en) * 2017-09-27 2020-03-12 Novartis Ag Parenteral formulation comprising siponimod

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3459731A (en) * 1966-12-16 1969-08-05 Corn Products Co Cyclodextrin polyethers and their production
IL27947A (en) * 1967-05-09 1972-07-26 Weitzman J Method for the production of thermoplastic resin particles and of mixtures of such particles with additives
JPS56115855A (en) * 1980-02-19 1981-09-11 Toyota Motor Corp Method and apparatus for controlling ignition timing of engine
US4383992A (en) * 1982-02-08 1983-05-17 Lipari John M Water-soluble steroid compounds
US4659696A (en) * 1982-04-30 1987-04-21 Takeda Chemical Industries, Ltd. Pharmaceutical composition and its nasal or vaginal use
HU191101B (en) * 1983-02-14 1987-01-28 Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt,Hu Process for preparing water-soluble cyclodextrin polymers substituted with ionic groups
IE62095B1 (en) * 1988-03-29 1994-12-14 Univ Florida Pharmaceutical formulations for parenteral use
FR2647343B1 (fr) * 1989-05-24 1994-05-06 Rhone Poulenc Sante Nouvelle forme pharmaceutique poreuse et sa preparation
US5216011A (en) * 1989-09-01 1993-06-01 Bristol-Myers Squibb Co. Stable solutions of mitomycin c
DE4138042C2 (de) * 1991-11-19 1993-10-14 Biotechnolog Forschung Gmbh Epothilone, deren Herstellungsverfahren sowie diese Verbindungen enthaltende Mittel
CA2086874E (en) * 1992-08-03 2000-01-04 Renzo Mauro Canetta Methods for administration of taxol
JPH0753396A (ja) * 1993-08-19 1995-02-28 Ensuiko Sugar Refining Co Ltd タキソールのサイクロデキストリン包接物，その製造法および用途
CA2092271C (en) * 1993-03-09 2009-10-13 Eddie Reed Use of g-csf for treating taxol side-effects
HU213200B (en) * 1993-05-12 1997-03-28 Chinoin Gyogyszer Es Vegyeszet The cyclodextrin or cyclodextrin derivative cluster complexes of taxol, taxotere, or taxus, pharmaceutical preparations containing them and process for their production
US5565478A (en) * 1994-03-14 1996-10-15 The United States Of America As Represented By The Department Of Health & Human Services Combination therapy using signal transduction inhibitors with paclitaxel and other taxane analogs
FR2718963B1 (fr) * 1994-04-25 1996-05-24 Rhone Poulenc Rorer Sa Nouvelle composition pharmaceutique à base de taxoïdes.
US5616330A (en) * 1994-07-19 1997-04-01 Hemagen/Pfc Stable oil-in-water emulsions incorporating a taxine (taxol) and method of making same
HUT73844A (en) * 1994-11-11 1996-09-30 Chinoin Gyogyszer Es Vegyeszet New taxol complexes and pharmaceutical compositions containing them
JP3934705B2 (ja) * 1995-05-26 2007-06-20 ノバルティス ファーマ株式会社 サイクロデキストリン組成物
EP1440973A3 (de) * 1995-11-17 2004-10-20 Gesellschaft für biotechnologische Forschung mbH (GBF) Epothilonderivate, Herstellung und Mittel
US5977163A (en) * 1996-03-12 1999-11-02 Pg-Txl Company, L. P. Water soluble paclitaxel prodrugs
US5877205A (en) * 1996-06-28 1999-03-02 Board Of Regents, The University Of Texas System Parenteral paclitaxel in a stable non-toxic formulation
JP4579351B2 (ja) * 1996-12-03 2010-11-10 スローン−ケッタリング インスティトュート フォア キャンサー リサーチ エポチロンの合成とその中間体及びその類似物並びにその使用
US6441186B1 (en) * 1996-12-13 2002-08-27 The Scripps Research Institute Epothilone analogs

Also Published As

Publication number Publication date
TR200002299T2 (tr) 2000-11-21
CL2003002786A1 (es) 2005-02-04
CO4920246A1 (es) 2000-05-29
ITMI990208A1 (it) 2000-08-04
PL201329B1 (pl) 2009-03-31
BR9907647A (pt) 2000-11-14
MY125921A (en) 2006-08-30
SK287487B6 (sk) 2010-11-08
KR20010040534A (ko) 2001-05-15
RU2214246C2 (ru) 2003-10-20
ID26549A (id) 2001-01-18
FR2774909B1 (fr) 2000-07-28
WO1999039694A3 (en) 1999-09-23
FR2774909A1 (fr) 1999-08-20
PE20000272A1 (es) 2000-04-17
NO20003930D0 (no) 2000-08-03
CA2320182A1 (en) 1999-08-12
US20080221065A1 (en) 2008-09-11
NO20100302L (no) 2000-10-04
AU2722699A (en) 1999-08-23
TW457095B (en) 2001-10-01
NZ506389A (en) 2003-07-25
US20060127423A1 (en) 2006-06-15
JP2010090147A (ja) 2010-04-22
IT1313549B1 (it) 2002-09-09
US20070060627A1 (en) 2007-03-15
ATE431733T1 (de) 2009-06-15
CZ303168B6 (cs) 2012-05-09
HK1033809A1 (en) 2001-09-28
KR100669174B1 (ko) 2007-01-17
ES2324378T3 (es) 2009-08-05
HUP0101564A3 (en) 2002-06-28
EP1052974B1 (en) 2009-05-20
CN1292683A (zh) 2001-04-25
IL137550A0 (en) 2001-07-24
SI1052974T1 (sl) 2009-10-31
BR9907647B1 (pt) 2014-04-01
CN100396276C (zh) 2008-06-25
US20030203876A1 (en) 2003-10-30
MXPA00007681A (es) 2003-07-14
HUP0101564A2 (hu) 2001-11-28
NO329376B1 (no) 2010-10-04
PT1052974E (pt) 2009-08-07
DK1052974T3 (da) 2009-08-10
JP4644364B2 (ja) 2011-03-02
JP2002502810A (ja) 2002-01-29
KR20080016756A (ko) 2008-02-21
EP1052974A2 (en) 2000-11-22
CY1109311T1 (el) 2014-07-02
AU753519B2 (en) 2002-10-17
BE1012140A3 (fr) 2000-05-02
AR017979A1 (es) 2001-10-24
IL137550A (en) 2010-06-30
CN1623543A (zh) 2005-06-08
DE69940904D1 (de) 2009-07-02
KR20060002022A (ko) 2006-01-06
PL342629A1 (en) 2001-06-18
US20110124691A1 (en) 2011-05-26
CZ20002834A3 (cs) 2000-11-15
SK11702000A3 (sk) 2001-01-18
CA2320182C (en) 2008-11-25
WO1999039694A2 (en) 1999-08-12
SK287775B6 (sk) 2011-09-05

Similar Documents

Publication Publication Date Title
NO20003930L (no) Sammensetninger som inneholder organiske forbindelser
NO20004299D0 (no) Organiske forbindelser
NO20014412L (no) Forbindelser nyttige som anti-inflammatoriske midler
DK2253620T3 (da) Substituerede 3-cyanoquinoliner som protein-tyrosinkinase-inhibitorer
LTPA2009006I1 (lt) Trombopoetino junginiai
ATE229954T1 (de) Betacarbolinverbindungen
FI981011L (fi) Uudet koostumukset
ID28266A (id) Senyawa-senyawa amidin
ATE367793T1 (de) Schweisshemmende zusammensetzungen
PT1069913E (pt) Composicoes oftalmicas gelificantes contendo goma xantana
DE69905038D1 (de) Cyclische boroprolinverbindungen
ITMI992711A0 (it) Composti organici
AR028563A1 (es) Compuestos heterociclicos que contienen n
NO20021637L (no) Kjemikalske forbindelser
EE200000492A (et) Kristalsete orgaaniliste ühendite stabiilsed kindla kujuga osakesed
DE69832516D1 (de) Isoflavon-enthaltende zusammensetzungen
DE69836106D1 (de) Stanolester enthaltende Zusammensetzungen
DE69927758D1 (de) Imidosilan-Zusammensetzungen
DK0975623T3 (da) Indazolamidforbindelser som sertoninerge midler
NO991821L (no) Substituerte tricykliske forbindelser
NO20005006L (no) Kalsilytiske forbindelser
DE69908845D1 (de) Fotoresistzusammensetzung
ID27889A (id) Komposisi-komposisi kopolimer polisiklik
DK1086097T3 (da) Sulfonylbenzenforbindelser som anti-inflammatoriske/analgetiske midler
NO20012526D0 (no) Sammensetninger som innbefatter cefuroksimaksetil

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees